Convergent Therapeutics
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer. The company's proprietary technology involves dual-targeted radionuclide therapy developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine, and licensed to Convergent by Cornell University. CONV 01-α, a monoclonal antibody conjugated with 225Ac, a radioactive alpha particle emitter, was specifically designed to bind to the prostate-specific membrane antigen (PSMA). A key functional feature of CONV 01-α is that, once bound to PSMA, it becomes internalized, thereby delivering its powerful radioactive payload directly into the prostate cancer cells. CONV 01-α is covered by multiple issued U.S. and foreign patents. If FDA-approved, CONV 01-α would be the first antibody approved to direct a radioisotope to prostate cancer and the first drug approved for the use of 225Ac in a cancer treatment.
Domain
convergentrx.com
Country
United StatesIndustry
Health CareEmployees
1-10
Last Funding
$40.0M
Founded
2020
Tech Stack (18 technologies)
Frequently Asked Questions
What technologies does Convergent Therapeutics use?+
Convergent Therapeutics uses 18 technologies including Google Analytics, Google Tag Manager, WordPress.
What industry is Convergent Therapeutics in?+
Convergent Therapeutics operates in the Health Care industry.
Where is Convergent Therapeutics based?+
Convergent Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026